Mar 28, 2022 / 05:00PM GMT
Paul Matteis - Stifel Financial Corp. - Analyst
Thank you very much, everybody, for continuing on. It's my pleasure, as always, to be hosting the Dyne executive management team, focused on neuromuscular diseases. And looking forward to a great conversation.
Maybe we can start, Josh, by having you give a quick overview and update on the lead programs and then we can get into more specifics. Is that cool?
Josh Brumm - Dyne Therapeutics, Inc. - President & CEO
Yeah, happy to do it. And Paul, thanks again to you and Stifel for having us today. We are really excited to be here. Just to remind everyone before we start that we will be making forward-looking statements. So as always, please refer to our SEC filings for more information.
So as always, it's exciting times for us here at Dyne. As you know, it's just over three years we've moved from concepts, preparing down to the clinic and multiple programs. We've been driven by our commitment to patients, our urgency to deliver the new hope for patients. And that will continue to guide our work
Dyne Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers